On August 27, 2019 CERENIS Therapeutics reported following the Extraordinary General Meeting of 21 June 2019, the shareholders of CERENIS Therapeutics approved the proposal for a new company name, which is now ABIONYX Pharma (Press release, ABIONYX Pharma, AUG 27, 2019, View Source [SID1234639900]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Beginning on 29 August 2019, the name, ISIN code and symbol/mnemonic of the share listed on Euronext Paris will be as follows:
– Share name: ABIONYX Pharma (replacing CERENIS Therapeutics)
– ISIN code of the share: FR0012616852 (unchanged)
– Stock symbol / Mnemonic code of the action: ABNX (replacing CEREN).

ABIONYX Pharma is a new generation biotech company that seeks to leverage a rich portfolio of clinical and preclinical programs inherited from the assets of CERENIS Therapeutics, to focus on the discovery and development of innovative therapies.